Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro

被引:37
作者
Girasole, G
Giuliani, N
Modena, AB
Passeri, G
Pedrazzoni, M
机构
[1] Univ Parma, Cattedra Med Interna, Dipartimento Med Interna & Sci Biomed, I-43100 Parma, Italy
[2] Univ Parma, Ist Ginecol & Ostetr, I-43100 Parma, Italy
关键词
D O I
10.1046/j.1365-2265.1999.00896.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Interleukin-6 (IL-6) seems to be a key mediator of the increased bone loss that follows loss of ovarian function, Based on this and on evidence that oestrogen deficiency may also increase cell sensitivity to IL-6, we studied the effects of ovariectomy and of oestrogen replacement therapy on the serum levels of IL-6 and of soluble IL-6 receptor (sIL-6R) in vivo. DESIGN AND PATIENTS Thirty-seven fertile women undergoing surgery for benign uterine diseases were divided into 3 groups and monitored for 12 months: hysterectomized women (n = 9), ovariectomized untreated women (n = 12) and ovariectomized women starting treatment with transdermal estradiol (E-2, 50 mu g/d) 1 month after surgery (n = 16), RESULTS Hysterectomy alone caused no significant changes of sIL6R whereas serum levels of sIL-6R rose progressively after ovariectomy (mean +/- SEM: 31 +/- 9% and 38 +/- 7% over baseline, at 6 and 12 months, respectively; P<0.01). Oestrogen replacement therapy prevented the increase of sIL6R over a 1-year period. A similar pattern was also found for serum IL-6 but the changes did not reach statistical significance. In ovariectomized (OVX) women there were significant correlations between serum sIL-6R levels and FSH (r = 0.59; P < 0.01), oestradiol (r = -0.43; P < 0.01), testosterone (r = -0.41; P < 0.05), osteocalcin (r = 0.42; P < 0.05) and bone alkaline phosphatase (r = 0.44; P < 0.05). To examine whether oestrogen directly regulates sIL-6R secretion by bone cells, we studied in vitro the basal and phorbol ester (PMA) stimulated release of sIL-6R in a human osteoblastic cell-line (MG-63) and in a tumour-derived osteoclastic cell line (GCT-51), Osteoblastic (but not osteoclastic) cells spontaneously produced considerable amounts of sIL-6R and the protein kinase-C activator PMA (10(-8) M) increased the release of sIL-6R by osteoblasts more than 3-fold, More strikingly, 17 beta E-2 (but not 17 alpha) significantly inhibited both the spontaneous- and PMA-induced release of sIL-GR by osteoblastic cells (P < 0.05). CONCLUSIONS These results indicate that oestrogen loss causes alterations of the IL-6 system, and that sIL-6R is under the direct inhibitory control of oestrogens both in vivo and in vitro.
引用
收藏
页码:801 / 807
页数:7
相关论文
共 38 条
[1]   INCREASED CYTOKINE SECRETION BY HUMAN BONE-MARROW CELLS AFTER MENOPAUSE OR DISCONTINUATION OF ESTROGEN REPLACEMENT [J].
BISMAR, H ;
DIEL, I ;
ZIEGLER, R ;
PFEILSCHIFTER, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (11) :3351-3355
[2]   EFFECT OF ESTROGEN REPLACEMENT ON BONE METABOLISM AND CYTOKINES IN SURGICAL MENOPAUSE [J].
CANTATORE, FP ;
LOVERRO, G ;
INGROSSO, AM ;
LACANNA, R ;
SASSANELLI, E ;
SELVAGGI, L ;
CARROZZO, M .
CLINICAL RHEUMATOLOGY, 1995, 14 (02) :157-160
[3]   In vitro secretion of cytokines by human bone marrow:: Effects of age and estrogen status [J].
Cheleuitte, D ;
Mizuno, S ;
Glowacki, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) :2043-2051
[4]   SERUM-SOLUBLE INTERLEUKIN-6 (IL-6) RECEPTOR AND IL-6 SOLUBLE IL-6 RECEPTOR COMPLEX IN SYSTEMIC JUVENILE RHEUMATOID-ARTHRITIS [J].
DEBENEDETTI, F ;
MASSA, M ;
PIGNATTI, P ;
ALBANI, S ;
NOVICK, D ;
MARTINI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :2114-2119
[5]   Interleukin-6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblast cultures [J].
Franchimont, N ;
Rydziel, S ;
Delany, AM ;
Canalis, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :12144-12150
[6]   SOLUBLE INTERLEUKIN-6 RECEPTOR IN BIOLOGICAL-FLUIDS FROM HUMAN-ORIGIN [J].
FRIELING, JTM ;
SAUERWEIN, RW ;
WIJDENES, J ;
HENDRIKS, T ;
VANDERLINDEN, CJ .
CYTOKINE, 1994, 6 (04) :376-381
[7]   INCREASED AND HIGHLY STABLE LEVELS OF FUNCTIONAL SOLUBLE INTERLEUKIN-6 RECEPTOR IN SERA OF PATIENTS WITH MONOCLONAL GAMMOPATHY [J].
GAILLARD, JP ;
BATAILLE, R ;
BRAILLY, H ;
ZUBER, C ;
YASUKAWA, K ;
ATTAL, M ;
MARUO, N ;
TAGA, T ;
KISHIMOTO, T ;
KLEIN, B .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (04) :820-824
[8]   17-BETA-ESTRADIOL INHIBITS INTERLEUKIN-6 PRODUCTION BY BONE MARROW-DERIVED STROMAL CELLS AND OSTEOBLASTS INVITRO - A POTENTIAL MECHANISM FOR THE ANTIOSTEOPOROTIC EFFECT OF ESTROGENS [J].
GIRASOLE, G ;
JILKA, RL ;
PASSERI, G ;
BOSWELL, S ;
BODER, G ;
WILLIAMS, DC ;
MANOLAGAS, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (03) :883-891
[9]   Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle [J].
Gorai, I ;
Taguchi, Y ;
Chaki, O ;
Kikuchi, R ;
Nakayama, M ;
Yang, BC ;
Yokota, SP ;
Minaguchi, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) :326-332
[10]   Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - A clinical research center study [J].
Grey, A ;
Mitnick, MA ;
Shapses, S ;
Ellison, A ;
Gundberg, C ;
Insogna, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3450-3454